Unlock unparalleled growth potential with pioneering investments in the third wave of drug reform.
Ride the Wave: Inside the exciting world of Third Wave drug reform investing - discover news, deals, and policy shifts shaping the future.
We provide:
The latest news
Market insights
Unique insights
Investment opportunities
Market Opportunity
The Third Wave of drug reform creates a 700+ billion opportunity for investors.
Sector | Market Size Estimate in USD | |
---|---|---|
Medical Cannabis | 22B in 2023¹ | 97B by 2033¹ |
Recreational Cannabis | 24B in 2023² | 49B by 2028² |
Illicit Drugs | 652B in 2022⁶ | - |
Ketamine | 9B in 2022³ | 26B by 2030⁴ |
Psilocybin | 1.1B in 2022⁵ | 3.2B by 2030⁷ |
LSD | 380M in 2022⁵ | - |
MDMA | 80M in 2022⁵ | 136B USD⁹ |
DMT | 300M in 2022⁵ | - |
TOTAL: |
3 Waves of Drug Reform
First Wave
Decriminalization of Marijuana
This wave focused on reducing legal penalties and eventually legalizing the use of marijuana, often initially for medicinal purposes and later for recreational use, reflecting a shift in public perception about its relative harm and potential benefits.
2013-2018
Approximately $100 billion of value created and early investors generated 1,000s of % returns.
Second Wave
Decriminalization of Psychedelics
This phase involved the gradual reduction of legal restrictions on psychedelics like psilocybin and LSD, often driven by emerging research suggesting therapeutic benefits for mental health conditions and a re-evaluation of their societal and cultural impacts.
2019-2022
Approximately $20 billion of value created and early investors generated 1,000s of % returns on invested capital.
Third Wave
Decriminalization of Other Drugs
The most recent wave represents a broader shift towards decriminalizing a range of previously illegal substances, influenced by arguments for harm reduction, the failures of the war on drugs, and a growing emphasis on treating drug use as a public health issue rather than a criminal one.
2023-Present
Early investors stand to profit significantly from decriminalization efforts worldwide.
Industry News
We have highlighted 3 front-runners in the sector for you to learn more about which are featured in our industry report:
Opportunities
Led by pioneers in the cannabis and psychedelics industries, Safe Supply is the first venture capital firm investing in the burgeoning safe supply ecosystem, the third wave of drug reform and an end to the war on drugs.
Harbour is disrupting and growing multi-billion-dollar industries in pharma, food & beverage, nutraceuticals, and sustainable agricultural fertilizer as the only Canadian coca leaf importer and processor.
Safety Strips is your trusted partner in ensuring drug safety. They are dedicated to combating the growing opioid crisis by providing a reliable solution for detecting fentanyl in your supply.
Watch Now
Safe Supply Ecosystem
The streaming model will allow Safe Supply Streaming to capitalize on deals across the value chain and being first to market gives us strong foundation to capitalize the balance sheet.
Investing Across the Value Chain
Safe Supply Streaming uses stream financing to scale high-integrity narcotics, wellness, healthcare & biotechnology businesses to support Health Canada and the Provincial Government in creating a $5+ billion legal narcotics / safe supply industry in British Columbia.
Regulations
Canada
In 2023, Health Canada granted an exemption under the Controlled Drugs and Substances Act to the Province of B.C. This is effective from January 31, 2023 to January 31, 2026. Under this exemption, adults (18 years and older) in B.C. are not arrested or charged for possessing small amounts of certain illegal drugs for personal use. The illegal drugs covered by the exemption include opioids (such as heroin, morphine, and fentanyl), crack and powder cocaine, methamphetamine (Meth), MDMA (Ecstasy).
Portugal
In 2001, Portugal decriminalized the personal possession of all drugs as part of a wider re-orientation of policy towards a health-led approach. Possessing drugs for personal use is instead treated as an administrative offence, meaning it is no longer punishable by imprisonment and does not result in a criminal record and associated stigma.1 Drugs are, however, still confiscated and possession may result in administrative penalties such as fines or community service.
Australia
From July 1, 2023, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions. The Therapeutic Goods Administration (TGA) will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression.
Switzerland
Switzerland's capital city, Bern, has signalled its intent to conduct a scientific pilot trial of controlled cocaine sales. With 43 votes to 18, the city parliament approved a motion from the Alternative Left to extend trials with cannabis to the future legal sale of cocaine. Despite recognising that cocaine is a harmful drug, Bern politicians believe that supervised sales could lead to better control of the narcotic.
United States
On January 4, 2023, several changes related to the passing of Colorado Proposition 122 went into effect that could impact the Centennial State’s economy, law enforcement and its healthcare system as it relates to alternative therapies for treating mental health conditions. adults ages 21 and over no longer face criminal penalties under Colorado state or local laws for possession or personal use of “natural medicine” found in psychedelic (magic) mushrooms, including: psilocybin, psilocin, dimethyltryptamine (DMT), and ibogaine.
Download “The Third Wave Opportunity of Drug Reform” Industry Report
This report focuses on the evolving landscape of drug reform, specifically highlighting the third wave of the opioid crisis. It delves into the significant investment opportunities emerging from this wave, driven by changes in drug laws and public perception around substances like cannabis, psychedelics, and opioids.
“The third wave of drug reform presents a groundbreaking opportunity for forward-thinking investors to invest in companies at the forefront of this transformation.”
— Bill Panagiotakopoulos, CEO, Safe Supply